Drug Name: Lytgobi
Active Ingredient: futibatinib
Indications: To treat intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements
Approval Date: 9/30/2022
Company: Taiho Oncology, Inc
Learn more: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/214801Orig1s000lbledt.pdf